Abstract
The Medical Research Council Working Party on Embryonal Tumours in childhood, (Chairman: Professor R. S. Illingworth) is currently planning two therapeutic trials in Wilm's tumour (nephroblastoma) and neuroblastoma. The trial of treatment of neuroblastoma is designed to investigate whether the regression that sometimes occurs in this disease is a consequence of an immune reaction developed against the tumour and if so whether this immunity can be increased by immunotherapy. There is experimental evidence that neuroblastomas contain tumour specific antigens against which an immune reaction may be stimulated, and also that the immune system is more likely to succeed in eradicating a tumour when the number of residual malignant cells in the body is low.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
